DEERFIELD, Ill., January 7, 2008 — Baxter Healthcare Corporation today announced an agreement with Nycomed that grants Baxter exclusive rights to market and distribute the company’s TachoSil® patch in the United States. TachoSil is a patented Nycomed product, which is currently available in more than 50 markets outside of the United States including Europe and Japan. The product is a fixed combination of a collagen patch coated with human thrombin and fibrinogen. It is used in a variety of surgical procedures to seal tissue and control bleeding, requires little preparation and can be stored at room temperature. The currently approved indication in Europe is “for supportive treatment in surgery for improvement of hemostasis where standard techniques are insufficient.” TachoSil is not yet an approved product in the United States.
TachoSil® is a ready-to-use surgical patch that allows haemostasis to be achieved quickly and easily. TachoSil® is the only ready-to-use fixed combination of a collagen sponge coated with a dry layer of the human coagulation factors fibrinogen and thrombin. TachoSil® achieves haemostasis in 3-5 minutes and has several distinct advantages compared with current supportive techniques.
No comments:
Post a Comment